Skip to Content

GlaxoSmithKline PLC GSK

Rating as of

Morningstar’s Analysis

Valuation
Currency in GBX
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Large-Cap Biopharma Capital Allocation Supports Primarily Wide-Moat Industry

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

The majority of the large-cap biopharma firms have moats, but almost all the drugs currently sold by the group will face generic competition over the next two decades, making successful capital allocation (evaluated by our capital allocation methodology) critically important in securing the current strong moat ratings within the group. We believe the patent life of drugs (typically 20 years, but with many years used during development) makes the biopharma group particularly reliant on successful redeployment of capital because of the need to constantly reinvent drug portfolios. We view a key part of successful capital allocation at big biopharma companies as a combination of (1) sound internal research and development (both in magnitude of investment and strategically focused in innovative therapeutic areas) and (2) successful external acquisitions and partnerships. The combination of successful internal development and external deals allows the big biopharma industry to consistently reinvent product portfolios and secure economic moats, protecting high returns on invested capital.

Read Full Analysis

Company Profile

Business Description

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

Contact
980 Great West Road
Brentford, Middlesex, TW8 9GS, United Kingdom
T +44 2080475000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type
Employees 94,066

Related